Metabolite Quantification

Cristina Cudalbu

Laboratory of Functional and Metabolic Imaging, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
Email: cristina.cudalbu@epfl.ch

Localized proton magnetic resonance spectroscopy (^{1}H MRS) became an important tool for investigating brain metabolism non-invasively. In animal models, high field ^{1}H MRS allows detection of almost 20 metabolites [1-4], also called the neurochemical profile (taurine (Tau), creatine (Cr), phosphocreatine (PCr), phosphocholine (PCho), glycerophosphocholine (GPC), glutamate (Glu), glutamine (Gln), myo-inositol (Ins), ascorbate (Asc), alanine (Ala), aspartate (Asp), γ-aminobutyrate (GABA), glutathione (GSH), N-acetylaspartate (NAA), N-acetylaspartylglutamate (NAAG), glucose (Glc), lactate (Lac), phosphoethanolamine (PE) and glycine (Gly). Since brain metabolite concentrations can vary depending on the type of pathology, the usefulness of ^{1}H MRS has been demonstrated in many brain disorders, e.g., in hepatic encephalopathy, Alzheimer's, Huntington's, and Parkinson's diseases, acute traumatic brain injury, cancer, dementia, etc. [5-6]. The metabolite changes help to understand metabolic processes related to the studied pathologies and/or enable to monitor effect of treatment. At longer echo times (TE above 20 ms), the number of spectral lines, which can be used for quantification, is reduced. As a result, in most in vivo ^{1}H MRS studies only changes of NAA, Cr+PCr, Cho and Lac have been detected. Short-echo-time in vivo ^{1}H MRS spectra (TE=1-20 ms) contain more information due to minimal distortions of multiplets of coupled spin systems such as Glu, Gln, Ins, Glc, Asp, Ala, GABA, Asc, PE and Tau. Accurate and precise quantification of brain metabolites is challenging and depends on several parameters: hardware performance, pulse sequence design, adjustments of acquisition parameters, data processing and quantification strategies. The purpose of data processing is to estimate the signal amplitude or peak area of each metabolite in a given spectrum, which is proportional to the metabolite concentration. Then by using different quantification methods the signal amplitude or peak area is converted in tissue metabolite tissue concentration. Measurements at high magnetic field benefit from increased spectral dispersion and higher signal to noise ratio, which likely improve quantification precision and accuracy [1, 7-8]. However, due to overlap of proton signals from brain metabolites, sophisticated approaches for the separation of the metabolite signals are required. Consequently, metabolite concentrations are usually determined by fitting a measured in vivo ^{1}H MRS spectrum to a linear combination of spectra of individual metabolites (also called metabolite basis set). The metabolite basis set can be obtained either by measuring aqueous solutions of pure metabolites or by quantum-mechanical simulations using known spectral parameters [9].

In the present course an overview of the factors that should be considered when performing and evaluating metabolite quantification is given. The course will be structured in 6 sections:

1. Short description of the time domain and frequency domain algorithms.
2. Factors affecting the quality and reliability of in vivo spectra
3. Key points to consider during the quantification (lineshape correction, macromolecule contribution)
4. Quantification techniques

5. Quantification improvements at high magnetic fields
6. Pitfalls during the data processing

1. <u>Short description of the time domain and frequency domain algorithms</u>

Well-known time and frequency–domain algorithms [10-21] based on extensive prior knowledge are currently used for accurate quantification. The jMRUI software [22] working in the time domain which contains the AMARES [17] and QUEST [12] algorithms will be described and also some advises for fine tuning will be given. In addition, the AQSES algorithm [13] will be shortly presented. Then the frequency domain algorithm LCModel [10-11] and the main functionally will be described. The last algorithm which will be described is TDFDfit [15], an iterative nonlinear least-squares fitting algorithm in the frequency domain using time domain models for quantification of complex frequency domain MR spectra. The error estimates obtained from the model fitting (Cramer Rao lower bounds) will also be discussed [23-24]. Examples of short and long echo-time ^{1}H and ^{13}C NMR spectra [25] acquired at high magnetic field and processed using the above described algorithms will be given (Fig 1).


Fig. 1: A. One series of in vivo spectra acquired at 14.1T in the rat brain with different repetition times (TR) and a TE=2.8 ms (a) and the corresponding estimates using LCModel (b). A shifted Gaussian function (gf = 0.08, gfs = 0.04) was used for modest resolution enhancement. No baseline correction or preprocessing for water signal removal was applied; B. Coronal view of a rat brain showing a typical position of a volume of interest (a). One series of in vivo spectra acquired at 14.1T in the rat brain with different inversion times (TI), ranging from 0 to 1.8 s and a TE=20 ms (b) and the corresponding estimates using AMARES (c). For quantification purpose the in vivo data were Lorentzian line broadened with 20 Hz. No preprocessing for water signal removal was applied.

2. <u>Factors affecting the quality and reliability of in vivo spectra</u>

This part of the course will briefly present in some examples the main factors that can lead to poor spectral quality, artifacts and misinterpretation of spectra (i.e outer volume contamination, poor water suppression, eddy currents, etc) [26].

3. Key points to consider during the quantification (lineshape correction, macromolecule contribution)

Lineshape correction

Short echo-time ^{1}H MRS data often contain lineshape distortions due to residual eddy currents and magnetic field inhomogeneities [27-34]. In single voxel spectroscopy, the signal from the whole shimmed volume contributes to one spectrum. The lineshape is mostly given by signal coming from the well-shimmed part of VOI, but the poorly-shimmed (broad) contributions affect (broaden) the bottom part of the line. These lineshape distortions, if left uncorrected, lead to errors in the quantification when using methods that incorporate model function with specific lineshapes [35].

Macromolecule contribution

Spectra measured at short echo-times are further complicated by the presence of macromolecules (broad signals ascribed mainly to cytosolic proteins [36]), which further complicates the quantification. Reliable quantification of the macromolecule signals in short echo-time ^{1}H MRS spectra is particularly important at high magnetic fields for an accurate quantification of metabolite concentrations due to effectively increased spectral resolution of the macromolecule components. Consequently, an error in the macromolecule estimation can lead to substantial errors in the obtained metabolite concentrations [4, 37-38]. In addition, it is well known that changes in the macromolecule concentrations can be considered as disease markers [39-40].

Modelling the macromolecule contributions in an in vivo spectrum can be done using two main approaches. The macromolecule signal is approximated by a mathematical function and then included in the fit [10-11, 41-43], or is separately estimated in a pre-processing step [12-13, 23, 41, 44-47]. It is well known that these procedures provide only a mathematical approximation of the real in vivo macromolecule spectra [37-38, 48]. This mathematical approach can be satisfactory at low magnetic fields. However, more prior knowledge is needed to obtain an accurate estimation of the metabolite concentrations at higher magnetic fields, where the macromolecule spectrum is better resolved. In addition to the mathematical approximation of the macromolecules, a second approach was proposed, which provides the necessary prior knowledge. It is based on a separate acquisition of the in vivo macromolecule spectra using an inversion recovery method (a metabolite-nulled spectrum). Then, during the quantification step the in vivo acquired spectrum of macromolecules is either added to the basis-set [4, 37-38, 49-53] or subtracted from the in vivo signal [48, 54-55]. Small residuals attributed to metabolites are still observed in the metabolite-nulled spectra due to variability in longitudinal relaxation times of metabolites (T_1). Thus, knowledge of the T_1 relaxation times of metabolites is required for identification of these residual metabolite signals and subsequent removal by postprocessing.

Several studies compared the simulated and experimentally obtained spectra of macromolecules in the quantification of in vivo proton spectra acquired at different magnetic fields and quantified using different algorithms [37-38, 48]. They showed that an experimental estimation of the macromolecule spectrum can improve the quality of the fit. The absence of the measured macromolecule spectrum in the database can led to a large and unpredictable bias in concentrations of many metabolites. Even at the highest magnetic fields available for in vivo experiments, spectral overlap of proton signals from brain metabolites and macromolecules still

require an experimental assessment of macromolecular contribution to the proton spectrum for accurate metabolite quantification (Fig 2 and 3). The main reason of the poor mathematical estimation of macromolecules at high magnetic fields is due to the fact that the largely field-independent linewidth of the signals of macromolecules increasingly approaches that of metabolites. As can also be seen from references [1, 37-38, 56], an effectively increased spectral resolution of the macromolecule components can be observed at higher magnetic field strengths, making the estimation of the macromolecules by the means of mathematical approximations even more difficult.


Fig. 2: A representative 14.1T spectrum (320 averages) of rat brain measured from a VOI=3x4x4mm³ (blue line) combined with a) the built-in LCModel spline baselines obtained from fitting spectra of five rats, which are plotted in different colors; and with b) the measured in vivo macromolecule spectrum (green line). Note the difference in the macromolecules estimation around 2 ppm, 3.0 ppm, 3.2 ppm and 4 ppm.

4. Quantification techniques

We saw until now how to estimate the signal amplitude or peak areas of each metabolite in a given spectrum. Since the signal amplitude or peak area is proportional to the metabolite concentration, by using different quantification methods we can convert it in tissue metabolite concentration ($mmol/kg_{ww}$). Two main approaches will be discussed for the absolute quantification: the external concentration reference used mainly for X nuclei and the internal concentration reference used mainly for proton data [57-65]. Corrections to be done in case of different pathologies will also be discussed.

5. Quantification improvements at high magnetic fields

Several studies have investigated the increased spectral dispersion, the improvement in signal to noise ratio and the improved quantification precision and accuracy with increasing Bo [1, 7-8, 56, 66-70]. The improvements are important for low concentrated metabolites with overlapping spectral lines and for compounds with complex J-coupled spectral patterns. In this part of the course we will briefly discuss the improvements in human brain metabolite quantification at 7T and also those obtained at 14T in rat brain.

Fig 3: The LCModel analysis of a representative 14.1 T spectrum. The measured in vivo spectrum in the rat brain at 14.1T is shown in (a). The corresponding LCModel fits using the measured macromolecule spectrum and the built-in LCModel spline baseline are also displayed in (b) and (c), respectively. The traces below represent from top to bottom, measured (b) or modeled (c) macromolecules, residual baseline and the difference between the measured and fitted data (also called residue of the quantification). The fits of the individual metabolites are plotted in (d).

6. Pitfalls during the data processing

At the end of the course I will briefly present in examples some general pitfalls during data processing for each quantification algorithm: bad estimation of the macromolecules, bad assignment of the metabolites, etc.

References:

[1] Mlynárik V, Cudalbu C, Xin L and Gruetter R 2008 (1)H NMR spectroscopy of rat brain in vivo at 14.1Tesla: Improvements in quantification of the neurochemical profile. J. Magn. Reson. 194 163-8

[2] Tkác I, Henry PG, Andersen P, Keene CD, Low WC and Gruetter R 2004 Highly resolved in vivo 1H NMR spectroscopy of the mouse brain at 9.4 T. Magn Reson Med. 52(3) 478-84.

[3] Tkác I, Rao R, Georgieff MK and Gruetter R 2003 Developmental and regional changes in the neurochemical profile of the rat brain determined by in vivo 1H NMR spectroscopy. Magn Reson Med. 50(1) 24-32.

[4] Pfeuffer J, Tkáč I, Provencher S and Gruetter R 1999 Toward an in vivo neurochemical profile: Quantification of 18 metabolites in short echo-time 1H spectra of the rat brain. J. Magn. Reson. 141 104–20

[5] Thorsen F, Jirák D, Wang J, Syková E, Bjerkvig R, Øyvind Enger P, van der Kogel A and Hájek M 2008 Two distinct tumor phenotypes isolated from glioblastomas show different MRS characteristics. NMR Biomed. 21 830–8

[6] Ross B D and Michaelis T 1994 Clinical applications of magnetic resonance spectroscopy. Magn. Reson. Q. 10 191–247

[7] Tkác I, Oz G, Adriany G, Uğurbil K and Gruetter R 2009 In vivo 1H NMR spectroscopy of the human brain at high magnetic fields: metabolite quantification at 4T vs. 7T. Magn Reson Med.62(4) 868-79.

[8] Mekle R, Mlynárik V, Gambarota G, Hergt M, Krueger G and Gruetter R 2009 MR spectroscopy of the human brain with enhanced signal intensity at ultrashort echo times on a clinical platform at 3T and 7T. Magn Reson Med. 61(6):1279-85.

[9] Govindaraju V, Young K and Maudsley A A 2000 Proton NMR chemical shifts and coupling constants for brain metabolites. NMR Biomed. 13 129-53

[10] Provencher S W 1993 Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn. Reson. Med. 30 672-9

[11] Provencher S W 2001 Automatic quantitation of localized in vivo 1H spectra with LCModel. NMR Biomed. 14 260–4

[12] Ratiney H, Coenradie Y, Cavassila S, van Ormondt D and Graveron-Demilly D 2004 Time-domain quantitation of ^{1}H short echo-time signals: background accommodation. MAGMA 16 284-96

[13] Poullet J B, Sima D M, Van Huffel S and Van Hecke P 2007 Frequency-selective quantitation of short-echo time 1H magnetic resonance spectra. J. Magn. Reson. 186 293-04

[14] Soher BJ, Young K, Govindaraju V and Maudsley AA 1998 Automated spectral analysis III: application to in vivo proton MR spectroscopy and spectroscopic imaging. Magn. Reson. Med 40(6) 822-831.

[15] Slotboom J, Boesch C and Kreis R 1998 Versatile frequency domain fitting using time domain models and prior knowledge. Magn. Reson. Med. 39(6) 899–911.

[16] Young K, Govindaraju V, Soher BJ and Maudsley AA 1998 Automated spectral analysis I: formation of a prior information by spectral simulation. Magn. Reson. Med. 40(6) 812-815.

[17] Vanhamme L, van den Boogaart A and Van Huffel S 1997 Improved method for accurate and efficient quantification of MRS data with use of prior knowledge. J Magn Reson 129 35-43.

[18] Stanley JA, Drost DJ, Williamson PC and Thompson RT 1995 The use of a priori knowledge to quantify short echo in vivo 1H MR spectra. Magn Reson Med 34 17–24

[19] Bartha R, Drost DJ, Williamson PC 1999 Factors affecting the quantification of short echo in vivo 1H MR spectra: prior knowledge, peak elimination, and filtering. NMR Biomed 12 205–216

[20] de Graaf A. A. and Bovee WM 1990 Improved quantification of in vivo 1H NMR spectra by optimization of signal acquisition and processing and by incorporation of prior knowledge into the spectral fitting. Magn. Reson. Med. 15, 305–319

[21] de Beer R and van Ormondt D 1992 Analysis of NMR data using time domain fitting procedures. NMR Basic Princ Prog 26 201-248.

[22] Naressi A, Couturier C, Devos JM, Janssen M, Mangeat C, de Beer R and Graveron-Demilly D 2001 Java-based Graphical User Interface for the MRUI Quantitation. MAGMA 12(2-3) 141-152.

[23] Cavassila S, van Ormondt D and Graveron-Demilly D 2002 Cramer–Rao bound analysis of spectroscopic signal processing methods In Signal processing for magnetic resonance imaging and spectroscopy chap 22, ed Y Hong (Marcel Dekker)

[24] Cavassila S, Deval S, Huegen C, van Ormondt D and Graveron-Demilly D 2001 Cramér-Rao bounds: an evaluation tool for quantitation. NMR Biomed.14(4) 278-83.

[25] Henry PG, Oz G, Provencher S and Gruetter R 2003 Toward dynamic isotopomer analysis in the rat brain in vivo: automatic quantitation of 13C NMR spectra using LCModel. NMR Biomed. 16(6-7) 400-12.

[26] Kreis R 2004 Issues of spectral quality in clinical 1H-magnetic resonance spectroscopy and a gallery of artifacts. NMR Biomed. 17(6) 361-81.

[27] Terpstra M, Andersen PM and Gruetter R. 1998 Localized eddy current compensation using quantitative field mapping. J Magn Reson. 131(1) 139-43.

[28] Bartha R, Drost DJ, Menon RS and Williamson PC. 2000 Spectroscopic lineshape correction by QUECC: combined QUALITY deconvolution and eddy current correction. Magn Reson Med. 44(4) 641-5.

[29] Ordidge RJ and Cresshull ID 1986 The correction of transient B0 field shifts following the application of pulsed gradients by phase correction in the time domain. J Magn Reson 69 151–155.

[30] Jehenson P and Syrota A 1989 Correction of distortions due to pulsed magnetic field gradient-induced shift in B0 field by postprocessing. Magn Reson Med 12 253–256.

[31] de Graaf AA, van Dijk JE and Bovee WMMJ 1990 QUALITY: quantification improvement by converting lineshapes to the lorentzian type. Magn Reson Med 13 343–357.

[32] Klose U 1990 In vivo proton spectroscopy in presence of eddy currents. Magn Reson Med 14 26–30.

[33] Riddle WR, Gibbs SJ and Willcott MR 1992 Removing effects of eddy currents in proton MR spectroscopy. Med Phys 19 501–509

[34] Metz KR, LAM MM and WEBB AG Reference 2000 Deconvolution: A Simple and Effective Method for Resolution Enhancement in Nuclear Magnetic Resonance Spectroscopy. Concepts in Magnetic Resonance 21 21-42.

[35] Cudalbu C, Cavassila S, Rabeson H, van Ormondt D and Graveron-Demilly D 2008 Influence of measured and simulated basis sets on metabolite concentration estimates. NMR Biomed. 21(6) 627-36.

[36] Behar K L, and Ogino T 1993 Characterization of macromolecule resonances in the 1H NMR spectrum of rat brain. Magn. Reson. Med. 30 38-44

[37] Cudalbu C, Beuf O and Cavassila S 2009 In Vivo Short Echo Time Localized 1H MRS of the Rat Brain at 7 T: Influence of Two Strategies of Background-accommodation on the Metabolite Concentration Estimation using QUEST. J. Sign. Process. Syst. 55 25-34

[38] Cudalbu C, Mlynárik V, Xin L and Gruetter R 2009 Comparison of two approaches to model the macromolecule spectrum for the quantification of short TE 1H MRS spectra. Meas. Sci. Technol. 20 104034 (7pp).

[39] Ratiney H, Srinivasan R, Henry R G, Okuda D, Nelson S J and Pelletier D 2007 Early and Progressive Disease Marker in MS; results from a large cross-sectional spectroscopic imaging study at 3T. In American Academy of Neurology 59th Annual Meeting,(Boston, USA, May 2007) p 02.041

[40] Hakumäki J M, Gröhn O H J, Pirttilä T R M and Kauppinen R A 1996 Increased macromolecular resonances in the rat cerebral cortex during severe energy failure as detected by 1H nuclear magnetic resonance spectroscopy. Neurosci. Lett. 212 151-154

[41] Soher B J, Young K and Maudsley A A 2001 Representation of strong baseline contributions in 1H MR spectra. Magn. Reson. Med. 45 966–72

[42] Schubert F, Seifert F, Elster C, Link A, Walzel M, Mientusand S, Haas J and Rinneberg H 2002 Serial 1H-MRS in relapsing-remitting multiple sclerosis: effects of interferon-beta therapy on absolute metabolite concentrations. Magn. Reson. Mater. Phy. 14 213–22

[43] Lemmerling P, Vanhamme L, in't Zandt H J A, Van Huffel S and Van Hecke P 2002 Time-domain quantification of short-echo-time in-vivo proton MRS. Magn. Reson. Mater. Phy. 15 178–9

[44] Young K, Govindaraju V, Soher B J and Maudsley A A 1998 Automated spectral analysis II: application of wavelet shrinkage for characterization of non-parameterized signals. Magn. Reson. Med. 40 816–21

[45] Coenradie Y, de Beer R, van Ormondt D, Cavassila S, Ratiney H and Graveron-Demilly D 2002 Background-signal parametrization in vivo MR spectroscopy. Magn. Reson. Mater. Phy. 15 369

[46] Coenradie Y, de Beer R, van Ormondt D, Ratiney H, Cavassila S and Graveron-Demilly D 2002 Background-signal parametrization in vivo MR spectroscopy. In Proc. of ProRISC, IEEE Benelux, (Veldhoven, The Netherlands, 2002) p 248–54

[47] Stanley J A and Pettegrew J W 2001 Postprocessing method to segregate and quantify the broad components underlying the phosphodiester spectral region of in vivo ^{31}P brain spectra. Magn. Reson. Med. 45 390–6

[48] Gottschalk M, Lamalle L and Segebarth C 2008 Short-TE localized 1H MRS of the human brain at 3T: quantification of the metabolite signals using two approaches to account for macromolecular signal contributions. NMR Biomed. 21 507-17

[49] Hofmann L, Slotboom J, Boesch C and Kreis R 2001 Characterization of the macromolecular baseline in localized 1H-MR spectra of human brain. Magn. Reson. Med. 39 855–63

[50] Hofmann L, Slotboom J, Jung B, Maloca P, Boesch C and Kreis R 2002 Quantitative 1H magnetic resonance spectroscopy of human brain: influence of composition and parametrization of the basis-set in linear combination model-fitting. Magn. Reson. Med. 48 440–53

[51] Seeger U, Mader I, Nagele T, Grodd W, Lutz O and Klose U 2001 Reliable detection of macromolecules in single volume 1H NMR spectra of the human brain. Magn. Reson. Med. 45 948–54

[52] Seeger U, Klose U, Mader I, Grodd W and Nagele T 2003 Parametrized evaluation of macromolecules and lipids in proton MR spectroscopy of brain diseases. Magn. Reson. Med. 49 19–28

[53] Cudalbu C, Bucur A, Graveron-Demilly D, Beuf O and Cavassila S 2007 Comparison of two strategies of background-accommodation: Influence on the metabolite concentration estimation from in vivo Magnetic Resonance Spectroscopy data. In Conf Proc IEEE Eng. Med. Biol. Soc (Lyon, France, 2007) p 2077-80

[54] Kassem M N E and Bartha R 2003 Quantitative proton short-echo-time LASER spectroscopy of normal human white matter and hippocampus at 4T incorporating macromolecule subtraction. Magn. Reson. Med. 49 918–27

[55] Rabeson H, Ratiney H, Cudalbu C, Cavassila S, Capobianco E, de Beer R, van Ormondt D and Graveron-Demilly D 2006 Signal Disentanglement in In Vivo MR Spectroscopy: By Semi-Parametric Processing or by Measurement? In Proc. ProRISC, IEEE Benelux, (Veldhoven, The Netherlands, 2006) p 176-83

[56] Otazo R, Mueller B, Ugurbil K, Wald L and Posse S 2006 Signal-to-Noise Ratio and Spectral Linewidth Improvements Between 1.5 and 7 Tesla in Proton Echo-Planar Spectroscopic Imaging. Magn. Reson. Med. 56 1200–10

[57] Gruetter R, Adriany G, Choi IY, Henry PG, Lei H and Oz G 2003 Localized in vivo 13C NMR spectroscopy of the brain. NMR Biomed.16(6-7) 313-38

[58] Schwarcz A, Berente Z, Osz E and Dóczi T 2001 In vivo water quantification in mouse brain at 9.4 Tesla in a vasogenic edema model. Magn Reson Med. 46(6) 1246-9.

[59] Kreis RR, Ernst T and Ross BD 1993 Absolute quantitation of water and metabolites in the human brain. II. Metabolite concentrations. J Magn Reson 102 9–19.

[60] Kinoshita Y and Yokota 1997 A. Absolute concentrations of metabolites in human brain tumors using in vitro proton magnetic resonance spectroscopy. NMR Biomed 10 2–12.

[61] Tong Z, Yamaki T, Harada K and Houkin K 2004 In vivo quantification of the metabolites in normal brain and brain tumors by proton MR spectroscopy using water as an internal standard. Magn Reson Imaging. 22(7) 1017-24.

[62] Ernst T, Kreis R and Ross BD. 1993 Absolute quantification of water and metabolites in the human brain. I. Compartments and water. JMR-B 102 1–8.

[63] Brief EE, Moll R, Li DK and Mackay AL 2009 Absolute metabolite concentrations calibrated using the total water signal in brain (1)H MRS. NMR Biomed. 22(3) 349-54.

[64] Isobe T, Matsumura A, Anno I, Yoshizawa T, Nagatomo Y, Itai Y and Nose T 2002 Quantification of cerebral metabolites in glioma patients with proton MR spectroscopy using T2 relaxation time correction. Magn Reson Imaging.20(4) 343-9.

[65] Malucelli E, Manners DN, Testa C, Tonon C, Lodi R, Barbiroli B, Iotti S 2009 Pitfalls and advantages of different strategies for the absolute quantification of N-acetyl aspartate, creatine and choline in white and grey matter by (1)H-MRS. NMR Biomed. 5 [Epub ahead of print]

[66] Gruetter R, Weisdorf SA, Rajanayagan V, Terpstra M, Merkle H, Truwit CL, Garwood M, Nyberg SL and Uğurbil K 1998 Resolution improvements in in vivo 1H NMR spectra with increased magnetic field strength. J Magn Reson. 135(1) 260-4.

[67] Barker PB, Hearshen DO and Boska MD 2001 Single-voxel proton MRS of the human brain at 1.5T and 3.0T. Magn Reson Med 45 765–769.

[68] Bartha R, Drost DJ, Menon RS and Williamson PC 2000 Comparison of the quantification precision of human short echo time 1H spectroscopy at 1.5 and 4.0 Tesla. Magn Reson Med 44 185–192.

[69] Posse S, Otazo R, Caprihan A, Bustillo J, Chen H, Henry PG, Marjanska M, Gasparovic C, Zuo C, Magnotta V, Mueller B, Mullins P, Renshaw P, Ugurbil K, Lim KO and Alger JR 2007 Proton echo-planar spectroscopic imaging of J-coupled resonances in human brain at 3 and 4 Tesla. Magn Reson Med 58 236–244.

[70] Srinivasan R, Vigneron D, Sailasuta N, Hurd R and Nelson S 2004 A comparative study of myo-inositol quantification using LCmodel at 1.5 T and 3.0 T with 3 D 1H proton spectroscopic imaging of the human brain. Magn Reson Imaging 22 523–528.